uPAR as Anti-Cancer Target: Evaluation of Biomarker Potential, Histological Localization, and Antibody-Based Therapy

E-ISSN： 1873-5592|12|12|1744-1760

ISSN： 1389-4501

Source： Current Drug Targets, Vol.12, Iss.12, 2011-11, pp. : 1744-1760

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antibody-based cancer therapy

By Baxevanis Constantin N

Expert Opinion on Drug Discovery, Vol. 3, Iss. 4, 2008-04 ,pp. : 441-452

Informa Healthcare

Access to resources Recommend Favorite

Frequent expression of CD30 in extranodal NK/T‐cell lymphoma: Potential therapeutic target for anti‐CD30 antibody‐based therapy

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 166-173

John Wiley & Sons Inc

Access to resources Recommend Favorite

Antibody-based antiangiogenic cancer therapy

By Sanz Laura Álvarez-Vallina Luis

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 6, 2005-12 ,pp. : 1235-1245

Informa Healthcare

Access to resources Recommend Favorite

Urokinase Receptor (uPAR) Ligand based Recombinant Toxins for Human Cancer Therapy

Current Pharmaceutical Design, Vol. 17, Iss. 19, 2011-06 ,pp. : 1979-1983

Bentham Science Publishers

Access to resources Recommend Favorite

Par-4 as a potential target for cancer therapy

By Irby Rosalyn B Kline Christina LB

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 1, 2013-01 ,pp. : 77-87

Informa Healthcare

Access to resources Recommend Favorite